Abstract | Heterozygous mutations in the gene that encodes the transcription factor hepatocyte nuclear factor 1β (HNF1B) represent the most common known monogenic cause of developmental kidney disease. Renal cysts are the most frequently detected feature of HNF1B-associated kidney disease; however, other structural abnormalities, including single kidneys and renal hypoplasia, and electrolyte abnormalities can also occur. Extra-renal phenotypes might also be observed; consequently, HNF1B-associated disease is considered a multi-system disorder. Other clinical features include early-onset diabetes mellitus, pancreatic hypoplasia, genital tract malformations, abnormal liver function and early-onset gout. Heterozygous mutations in the coding region or splice sites of HNF1B, and complete gene deletion, each account for ~50% of all cases of HNF1B-associated disease, respectively, and often arise spontaneously. There is no clear genotype-phenotype correlation, consistent with haploinsufficiency as the disease mechanism. Data from animal models suggest that HNF1B has an important function during several stages of nephrogenesis; however, the precise signalling pathways remain to be elucidated. This Review discusses the genetics and molecular pathways that lead to disease development, summarizes the reported renal and extra-renal phenotypes, and identifies areas for future research in HNF1B-associated disease.
Introduction
Hepatocyte nuclear factor 1β (HNF1B) is a homeodomaincontaining transcription factor. HNF1B has known functions in nephron development and heterozygous mutations are the most common known monogenic cause of developmental renal disease. [1] [2] [3] [4] Renal cysts are the most commonly observed clinical feature in HNF1B-associated disease, and numerous affected individuals additionally exhibit early-onset diabetes mellitus; this observation led to the description of renal cysts and diabetes (RCAD) syndrome. 5 Since initial reporting of the early cases of HNF1B-associated disease in 1997, it has become evident that additional clinical features are also associated with mutations in HNF1B. [6] [7] [8] These features include pancreatic hypoplasia, 9 ,10 genital tract malformations, 11 abnormal liver function, 7, 12 hypomagnesaemia, 13 hyperuricaemia and early-onset gout. 14 HNF1B-associated disease is, therefore, considered to be a multi-system disorder ( Figure 1 ).
The discovery of HNF1B gene mutations as a cause of developmental renal disease arose from unexpected findings in the study of maturity-onset diabetes of the young (MODY). [6] [7] [8] MODY is a monogenic form of earlyonset diabetes mellitus that is typically diagnosed before the age of 25 years. MODY is inherited in an autosomal dominant manner and results from pancreatic β-cell dysfunction. 15 The most common cause of MODY is mutation of the gene encoding the transcription factor HNF1A, 16 which binds to the same DNA sequence as HNF1B, and both proteins show >80% sequence homology. 17 HNF1B was considered a good candidate gene for MODY cases without a known genetic cause and an HNF1B mutation associated with early-onset diabetes mellitus was first reported in a Japanese family in 1997. 6 Renal disease was also present in the three affected individuals in this family, which ranged in severity from persistent proteinuria to chronic kidney disease. Bilateral renal cysts were subsequently identified in the individual with proteinuria. 7 The associ ation of diabetes mellitus with non-diabetic renal disease was strengthened by the identification of two additional families with a heterozygous mutation in HNF1B. 8, 11 Many of the affected family members additionally exhibited abnormal liver function and genital malformations, providing the first evidence that a mutation in HNF1B could result in a multi-system disease.
This Review focuses on HNF1B-associated renal developmental disease. We first provide an outline of the molecular genetics of this disorder. We next discuss functional studies, including the use of animal models in determining the expression pattern of HNF1B during embryonic development. The various phenotypes thus far associated with HNF1B mutations are described and finally, we highlight key areas for future research.
as a homodimer or as a heterodimer with HNF1A to regulate gene expression. The HNF1B gene is located on chromosome 17q12 and the encoded protein has three distinct functional domains: the dimerization domain, the DNA binding domain, and the transactivation domain ( Figure 2 ). Genetic changes comprise base substitutions, and small insertions-deletions in 24 of 58 (41%) adult patients and 51 of 116 (44%) affected children or fetuses; deletions of the entire gene account for 34 of 58 (59%) adult patients and 65 of 116 (56%) affected children or fetuses. [1] [2] [3] 13, [18] [19] [20] [21] [22] [23] [24] More than 50 different HNF1B mutations have been reported, including missense, nonsense, frame-shift and splicing mutations (Figure 2 , Supplementary Table 1 ). The majority of identified mutations are clustered in the first four exons of the gene, with exons 2 and 4, and the intron 2 splice site being mutation site hotspots. 25 No correlation seems to exist between the type or position of the mutation and particular clinical features. 26 Expression of the phenotype can vary considerably between families harbouring the same HNF1B mutation as well as between affected members of individual families, which suggests that additional genetic and/or environmental modifiers might influence the HNF1B phenotype. Stochastic variation in temporal HNF1B gene expression during early development could also increase phenotypic diversity.
Whole-gene deletions of HNF1B were reported 8 years following the identification of the first coding mutation. 27 The region of chromosome 17 that encompasses the HNF1B gene is susceptible to genomic rearrangement, which is mediated by non-allelic homologous recombination between segmental duplications flanking a 1.5 Mb region. 28 This type of genomic rearrangement is not detected by conventional direct sequencing techniques and instead requires gene dosage analysis. Detection of both gene mutations and deletions will be facilitated by the increasing use of next generation sequencing technology. 29 Partial gene deletions have also been reported. 27 No evidence is available to suggest that patients with a whole-gene deletion exhibit a different phenotype to those with coding or splice site mutations. This finding is consistent with haploinsufficiency as the underlying disease mechanism. 20, 27 HNF1B-associated disease is generally considered to be inherited in an autosomal dominant manner. Nevertheless, whole-gene deletions, as well as coding and splice site mutations, can also arise spontaneously. 19, 26 The prevalence of spontaneous HNF1B deletion is reported to be as high as 50%, 18, 20 which explains why there is often no family history of renal disease or diabetes mellitus. The high frequency of de novo deletions is explained by the presence of flanking segmental duplications, and the increased rate of spontaneous mutations probably arises as a result of the decreased biological fitness of affected individuals. 28 Reduced fertility, as a result of genital tract malformations, has been reported among patients with HNF1B-associated disease; furthermore, the wide phenotypic variability might not be compatible with life, as is seen in cases of severe congenital abnormalities of the kidneys and urinary tract (CAKUT) detected on prenatal ultrasonography and leading to termination of pregnancy.
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Functional studies
The process of organ development is often highly conserved between different species. The zebrafish shows high conservation of renal organogenesis with mammals and is therefore a convenient model system for functional studies. Three mutant alleles of vhnf1, the zebrafish homologue of HNF1B, were isolated in a zebrafish insertional mutagenesis screen. These mutants formed renal cysts and exhibited an underdeveloped pancreas and liver. 31 The Xenopus laevis (frog) model system can also be used to study the development of the pronephros, the Figure 1 | Renal and extra-renal phenotypes frequently observed among patients with hepatocyte nuclear factor 1β-associated disease.
functional kidney throughout larval development, which is useful owing to its simplicity and ease of accessibility. Nine different HNF1B mutations, associated with various renal phenotypes in humans, have been evaluated in X. laevis. In vitro analysis showed that seven of the subsequent mutant proteins failed to bind DNA, whereas two retained an intact DNA-binding domain and could bind DNA efficiently. Intact DNA binding correlated with the ability of the mutant protein to form dimers with the wild-type protein and transactivate target genes. These modelled mutations all interfered with pronephros development to differing degrees when introduced into Xenopus embryos. The pattern of pronephros development seen in the developing embryo does not strictly correlate with the properties observed in vitro or in transfected cell lines, suggesting that functional studies in Xenopus may define features of the HNF1B transcription factor that are not detected in cultured cells. 32 The transactivation potential of HNF1B depends on the synergistic action of the histone-acetyltransferases CREB-binding protein (CBP) and p300/CBP-associated factor (PCAF). The transcriptional impairment of HNF1B mutants with normal DNA-binding activity correlated with the loss of its association with one of these co-activators in co-immunoprecipitation studies. The activity of these mutant proteins in cell lines was not increased by the synergistic action of CBP and PCAF. HNF1B-associated disease may therefore result not only from defective DNA binding but also from diminished transactivation function through impaired recruitment of co-activator proteins. 33 Investigation into the effect of HNF1B mutations within the intron 2 splice site was initially challenging owing to difficulties in accessing tissues with high levels of endogenous HNF1B expression. 14 These studies have been facilitated by the use of ectopic HNF1B transcription in Epstein-Barr virus-transformed lymphoblastoid cell lines; that is, making use of the presence of very low quantities of correctly spliced tissue-specific mRNAs in non-expressing tissues. This technique has been used to demonstrate how two mutations of the intron 2 splice donor site result in the deletion of exon 2 and are predicted to cause premature termination of the HNF1B protein. 34 Comparable levels of mRNA have been demonstrated in both renal tubule cells isolated from overnight urine and lymphoblastoid cells collected from the same patient with an HNF1B mutation. 35 Subsequent work has confirmed that measuring mRNA expression in urinary sediment can be a useful approach to assess the renal epithelial transcriptome in HNF1B-associated renal disease. 36 The role of HNF1B in renal development HNF1B is widely expressed in multiple fetal tissues and is required for visceral endoderm specification.
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HNF1A is expressed later than HNF1B and is activated only during organogenesis. 38 In adult mice and rats, these transcription factors are expressed in the liver, kidneys, pancreatic islets, stomach and intestine. HNF1B is predominantly expressed in the kidneys, but is also expressed in the gonads, thymus and lungs. HNF1A is most highly expressed in the liver. 39 Despite the high degree of homology between these two transcription factors and their shared DNA binding site, 17 mutations in HNF1B usually result in a multi-system disease, whereas mutations in HNF1A have to date solely been reported to cause MODY. This phenotypic variation is likely a reflection of the differential timing and localization of expression of HNF1A and HNF1B during development.
Accurate kidney development depends on appropriate interaction between the ureteric bud and metanephric mesenchyme. The ureteric bud gives rise to the ureter, renal pelvis and collecting duct, whereas the meta nephric mesenchyme gives rise to the nephron. 40 Renal development starts with the induction of the ureteric bud from the nephric duct following glial-derived neurotrophic factor (GDNF) secretion from the adjacent metanephric mesenchyme, which activates the receptor tyrosine kinase Ret via the co-receptor GDNF-family receptor α1. The renal collecting system is formed by the invasion of the ureteric bud into the metanephric mesenchyme, with subsequent elongation and branching. Groups of mesenchymal cells proximal to the ureteric bud tips form pretubular aggregates, which first differentiate into comma-shaped and S-shaped bodies, and finally into the Bowman capsule and tubules. 41 The exact role of HNF1B during this complex process remains to be fully determined. In situ hybridization studies using human tissue samples have shown that HNF1B mRNA is highly expressed in the fetal collecting ducts, with lower levels of expression in the metanephric mesenchyme. 42 Several mouse studies have suggested that Hnf1b has an important function during the early stages of urogenital development. 43, 44 Absence of Hnf1b expression in the ureteric bud can result in abnormal ureteric bud branching and a failure of surrounding mesenchymal cells to transition into epithelia, a key step in early nephrogenesis. 43 Hnf1b seems to act upstream of Wnt9b and Table 1 . Abbreviations: HNF1B, hepatocyte nuclear factor 1β; POU H , Pit-1Oct-1/2Unc-86 homeodomain; POU S , Pit-1Oct-1/2Unc-86 specific.
alters Wnt signalling, a pathway known to be crucial in early renal development. 43, 44 Various animal models of Hnf1b deficiency have been used to examine the role of HNF1B during development. Germline inactivation of Hnf1b in mouse embryos is lethal, with death at day 6.5-7.0 postconception. 37 Renalspecific inactivation of Hnf1b in mice results in poly cystic kidneys. This phenotype is associated with a marked reduction in the transcriptional activation of the cystic disease genes Umod, Pkhd1 and Pkd2, that contain DNA elements to which HNF1B normally binds. 45 Further work also suggests a link between Hnf1b and Pkhd1 during kidney development. Transgenic mice expressing a dominant-negative Hnf1b mutant gene under the control of a kidney-specific promoter develop renal cysts. The cells lining these cysts lack Pkhd1 mRNA; however, this transcript is present in surrounding morphologically normal tubules. 46 HNF1B is thought to have a role in tubular development within the nephron. In mice, inactivation of Hnf1b in the metanephric mesenchyme leads to the formation of aberrant nephrons. These nephrons are characterized by glomeruli with a dilated Bowman space directly connected to collecting ducts via a primitive tubule, owing to the absence of the proximal and distal tubules and loop of Henle. Lack of Hnf1b protein expression also results in deformed S-shaped bodies that lack the typical bulge of epithelial cells in the mid-limb, which usually gives rise to the proximal tubule and the loop of Henle. This phenotype might be associated with defective Ixr1, Osr2 and Pou3f3 gene expression plus abnormal Notch signalling activation. 47 The Notch signalling pathway is known to be important in tubular segmentation and glomerular formation. 48 
Renal phenotype
Prevalence CAKUT are common and a frequent cause of chronic kidney disease and end-stage renal disease (ESRD); they account for >40% of cases of chronic kidney disease in children in the US. 49, 50 The term CAKUT covers a broad range of disorders and several genes have been implicated in the pathogenesis of renal malformations, including HNF1B. Table 1 summarizes the prevalence of HNF1B-associated renal disease in several study cohorts of ≥50 individuals, where both mutation and deletion screening of HNF1B was performed. The mean overall detection rate of HNF1B gene anomalies was 19%, ranging from 5% to 31% depending on the phenotypic selection of the cohort. By contrast, HNF1B mutations and deletions are an infrequent cause of MODY and are likely to account for <1% of cases. 51 
Morphology
Considerable variation is seen in the phenotype of HNF1B-associated renal abnormalities, despite the single genetic aetiology. Morphological renal abnormalities are commonly identified by ultrasonography. MRI can be used in selected cases and might be useful in the detection of extra-renal clinical features, such as pancreatic structural abnormalities. 52 Prenatal ultrasonography can often detect clinical features of HNF1B-associated renal disease in the developing fetus, where the most frequently observed phenotype is isolated bilateral hyperechogenic kidneys of normal or slightly increased size. 19 In the postnatal period, the majority of these affected individuals have normal-sized or small kidneys with hyperechogenicity and/or renal cysts, which suggests a retardation of renal growth following birth. 4 Cystic disease, including cystic dysplasia, is the predominant renal phenotype in both paediatric and adult populations. In the largest case series described to date, cystic disease was present in 73% of patients with HNF1B-associated kidney disease. 4 The major caveat when determining the prevalence of different renal charac teristics is that no population-based data currently exist and the majority of the cohorts previously described were pre-selected for particular kidney abnormalities (see Table 1 for examples). Cysts are usually small in size, 18 often arising within the renal cortex, and are not reported to progressively increase in number over time. 22 Single kidneys were reported among five of 24 adults carrying HNF1B mutations, the largest series conducted so far of adults with HNF1B-associated disease. 22 Single kidneys Study cohorts of ≥50 subjects with renal disease were analysed. Both mutation and deletion screening of the HNF1B gene was performed on all subjects included in these cohorts. Abbreviations: eGFR, estimated glomerular filtration rate; SD, standard deviation.
were initially hypothesized to be the result of involution of multicystic dysplastic kidneys over time; however, unilateral renal agenesis has also been identified by prenatal fetal imaging in four of 56 affected cases. 4, 18 Other reported structural abnormalities include renal hypoplasia, horseshoe kidney (fusion of the two kidneys during embryonic development into a horseshoe-shaped structure) and duplex kidney. 3, 18, 20 Collecting system abnormalities, such as pelviureteric junction obstruction, have also been identified, but usually occur in conjunction with other renal structural abnormalities. 25 Isolated bilateral hydronephrosis and hydroureter have also been reported. 13 HNF1B mutations were found in two of 34 individuals with prune-belly syndrome, which is characterized by a triad of dilatation of the urinary tract, deficiency or absence of the abdominal wall musculature and bilateral undescended testes. [53] [54] [55] In a minority of cases, renal imaging can appear normal;
9,22,51 however, it is unclear how often this finding occurs as the majority of cohorts with HNF1B-associated disease that have been studied were pre-selected for kidney abnormalities. In view of the intra-familial variability in clinical features that is seen, it will be important in future studies to systematically collect phenotypic information from all affected family members as well as the proband.
Histology
Renal biopsies are not performed in many cases of HNF1B-associated disease as renal cysts, or other structural anomalies, are often visualized by imaging. A total of 19 histologic results have been reported in the literature to date. The majority of these biopsies were performed as part of explorative clinical investigation of unexplained renal impairment before a genetic diagnosis being established; others have resulted from post-mortem examination following termination of pregnancy. Considerable variation was observed in the histological diagnosis, including hypoplastic glomerulocystic kidney disease (cortical glomerular cysts with dilatation of the Bowman spaces and primitive glomerular tufts in ≥5% of the cysts) among six patients; [3] [4] [5] 56 oligomeganephronia (reduced number of enlarged nephrons) in three patients; 9, 11, 57 and cystic renal dysplasia in two patients. 30, 58 These different renal phenotypes are speculated to arise from abnormal nephron development. Other nonspecific features include interstitial fibrosis, enlarged glomeruli and/or nephrons and glomerular cysts.
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Malignancy Imaging to screen for chromophobe renal cell carcinoma (RCC), a rare subtype of kidney cancer, should be considered for individuals with HNF1B gene anomalies. Following the observation of chromophobe RCC in a patient with a known HNF1B mutation, 9 a series of 34 randomly selected renal neoplasms were screened for HNF1B gene inactivation. Biallelic inactivation was identified in one of 11 tissue samples owing to the development of a somatic HNF1B gene deletion in addition to a germline mutation. 59 Overexpression of HNF1B is common in clear cell ovarian cancer. 60 Furthermore, several genome-wide association studies have also linked genetic variation in the HNF1B region with a risk of endometrial and prostate cancer.
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Electrolyte abnormalities
Hypomagnesaemia
Hypomagnesaemia is a common feature of HNF1B-associated disease. 4, 13, 22 This condition was detected in eight of 18 (44%) children with HNF1B mutations under follow-up for renal malformation; hypomagnesaemia was accompanied by hypermagnesuria and hypocalciuria. With the exception of one patient who presented with tetany, symptoms attributable to hypomag nes aemia were not reported in the other cases. HNF1B regulates the transcription of FXYD2, a gene that encodes the γ subunit of the Na + /K + -ATPase and is involved in the reabsorption of magnesium in the distal convoluted tubule.
13, 65 A mutation in FXYD2 has been reported in one family to date with autosomal dominant hypomagnesaemia and hypocalciuria. 66 This finding suggests an additional role for HNF1B in the maintenance of tubular function.
Hyperuricaemia
Hyperuricaemia has been associated with disorders resulting from mutations to HNF1B, 14 although serum urate levels have not yet been systematically measured in a large cohort. Patients might additionally present with early-onset gout, and some affected individuals with hyperuricaemia, early-onset gout and renal disease meet established criteria for familial juvenile hyper uricaemic nephropathy, a condition usually caused by mutations in UMOD, which encodes uromodulin. 67 The cause of hyperuricaemia in HNF1B-associated disease is considered to reflect both altered urate transport in the kidney and an early manifestation of renal impairment. Mice with renal-specific inactivation of Hnf1b develop poly cystic disease and exhibit markedly reduced transcriptional activation of Umod. 45 The majority of causative mutations in UMOD that result in familial hyperuric aemic nephro pathy are considered to exert dominant negative effects; therefore, it remains unclear how the same phenotype is associated with HNF1B haploinsufficiency. 4 
Renal function
Renal function is usually impaired in HNF1B-associated disease but can range from normal to ESRD. A slowly progressive deterioration of renal function throughout adulthood has previously been described; a median yearly decline in the estimated glomerular filtration rate (eGFR) of 2.45 ml/min/1.73 m 2 was observed in a study of 27 adults with an HNF1B mutation and a wide variety of renal phenotypes. 22 Four patients (15%) in this series progressed to ESRD, which is consistent with the frequency reported in a systematic review (12.8%). 25 The age at diagnosis of ESRD remains unpredictable, and has even been reported in early childhood. 20 The impact of causative mutations in HNF1B on renal function in the paediatric population is difficult to interpret owing to the young age of the patients and the lack of long-term follow-up. HNF1B gene anomalies can also be associated with severe prenatal renal anomalies, which may result in oligohydramnios, pulmonary hypoplasia and renal failure. This situation can in turn lead to perinatal death, the requirement for early renal replacement therapy or parental request for termination of the pregnancy. 1, 4 Individuals with HNF1B-associated disease who are likely to require renal replacement therapy should be considered for renal transplantation. This patient group is at increased risk of developing new-onset diabetes after transplantation (NODAT), and an immunosuppressive regimen that avoids tacrolimus and reduces corticosteroid exposure might be beneficial. 68 Simultaneous pancreas and kidney (SPK) transplantation, a procedure usually reserved for patients with type 1 diabetes mellitus and ESRD, might be an option for patients with HNF1B-associated disease who present with both diabetes mellitus and ESRD. Three individuals with HNF1B-associated disease were successfully treated with either SPK or pancreas-after-kidney transplantation, and remained free from the requirement of insulin therapy 1 year after the procedure.
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Differential diagnosis
The differential diagnosis of HNF1B-associated kidney disease is large given the considerable vari ation in renal phenotypes. Here we discuss the most common presentations of HNF1B-associated kidney disease. Moderately enlarged bilateral hyperechogenic kidneys are often identified following prenatal ultra sono graphy; autosomal recessive and autosomal dominant polycystic kidney diseases are the main differential diagnoses in such cases. 52 To facilitate diagnosis, ultrasono graphy should also assess for any associated extra-renal abnormalities and a complete family history is useful, with particular emphasis placed on renal disease and diabetes mellitus. Renal cysts are usually visualized after birth; Table 2 summarizes the main differential diagnoses to consider depending on age at presentation. Individuals with HNF1B-associated kidney disease might present with other forms of renal tract malformation, including renal agenesis or hypoplasia. The differential diagnosis in these cases can include other multi-organ syndromes that are not covered in this Review, such as branchio-oto-renal syndrome and renal coloboma syndrome.
Extra-renal phenotypes
Diabetes mellitus HNF1B has an important function in the early development and differentiation of the pancreas. 71, 72 HNF1B gene anomalies can, therefore, result in both reduced endocrine and exocrine function. Diabetes mellitus is the most frequent extra-renal phenotype detected and usually presents following renal disease in patients with an HNF1B-associated disorder that was identified in childhood. The mean age at diagnosis of diabetes mellitus is 24 years, 25 but can vary from the neonatal period 73, 74 to late middle age. 26 In a cohort of 27 adult HNF1B mutation carriers with a median age of 35 years, diabetes was present in 13 individuals (48%); none of the patients in this series developed diabetic retinopathy or neuropathy before the close of the study. 22 Diabetes mellitus might manifest as NODAT and analysis of the HNF1B gene should be considered among individuals with unexplained CAKUT undergoing transplantation to improve post-transplantation management. 68 Presentation with diabetic ketoacidosis has also been described. 39 The majority of patients with HNF1B-associated diabetes mellitus respond poorly to sulphonylureas and so require treatment with insulin. 25, 75 By contrast, individuals with HNF1A-associated dia betes mellitus respond extremely well when treated with sulphonylureas. 76 The pathophysiology of diabetes mellitus reflects a combination of β-cell dysfunction and insulin resistance. Dysfunction of β-cells results in reduced insulin secretion, which is likely to be a consequence of pancreatic hypoplasia. 10 Decreased insulin secretion in utero leads to intrauterine growth retardation and low birth weight. 74 Patients with HNF1B mutations have reduced insulin sensitivity to endogenous glucose production but peripheral insulin sensitivity is normal. 77 This situation results in hyperinsulinaemia and associated dyslipidaemia, with raised levels of triglycerides and reduced levels of high-density lipoprotein. 75 Exocrine pancreatic dysfunction Pancreatic hypoplasia has been described in several individuals with HNF1B-associated disease. 9 Imaging studies have shown a reduced pancreatic structure, with less tissue corresponding to the body and tail of the pancreas and a slightly atrophic pancreatic head. 10 These characteristics are consistent with agenesis of the dorsal pancreas-the embryonic structure that gives rise to the pancreatic body, tail, and a small region of the head. Studies in mice investigating the mechanisms of pancreatic development have revealed that embryos completely deficient in Hnf1b had a significantly reduced dorsal pancreatic bud that was only transiently present, whereas the ventral bud was undetectable. 72 Two cases of complete pancreatic agenesis have been described in fetuses with severe renal abnormalities, which were found to have an HNF1B gene mutation following induced termination of the pregnancy. 1, 78 The majority of patients with pancreatic hypoplasia also have subclinical pancreatic exocrine dysfunction, as evidenced by faecal elastase deficiency. 9, 10 Detailed assessments of pancreatic function, using rapid endoscopic secretin stimulation tests and secretin-stimulated MRI, have confirmed this co-morbidity among patients with HNF1B-associated disease. 79 Pancreatic exocrine hypersecretion has also been observed in affected individuals, and could be a compensatory mechanism for diminished pancreatic volume. These data suggest that the small pancreas observed in individuals with HNF1B mutations might be the result of hypoplasia rather than atrophy.
Genital tract malformations
Genital malformations were described in some of the first cases of HNF1B-associated disease, providing an early clue that it is a multi-system disorder.
11 Such malformations are most common among females, and are usually caused by abnormalities in uterine development. 25 In a cohort of 108 females with congenital uterine abnormalities, heterozygous mutation or deletion of HNF1B was found in nine of 50 patients (18%) who had both uterine and renal abnormalities, but in none of the 58 cases with isolated uterine abnormalities. 24 In the female embryo, the Müllerian ducts develop into the uterus, fallopian tubes, cervix and the upper part of the vagina. Müllerian duct aplasia results in the formation of an underdeveloped, rudimentary uterus and vaginal aplasia, and affected individuals are infertile. 11 The corpus and cervix of the uterus and the upper third of the vagina are formed by fusion of the caudal parts of the Müllerian ducts. Failure of fusion can result in a bicorn uate uterus, uterus didelphys or a double vagina. 58, 80 HNF1B is also a candidate gene for MayerRokitansky-Küster-Hauser syndrome, which involves congenital aplasia of the uterus, cervix and upper vagina resulting in primary amenorrhoea and infertility. 81, 82 Various genital tract malformations, including crypt orchidism, agenesis of the vas deferens, hypospadias, epididymal cysts and asthenospermia, have been reported among males; 9, 22, 58 however, the potential implication of these associations with HNF1B mutations is unclear owing to the small number of reported cases.
Abnormal liver function
Liver dysfunction in association with HNF1B gene mutations has been clinically documented since the original Cystic dysplasia and multicystic dysplastic kidney are usually idiopathic but can also be seen in HNF1B-associated disease; renal ultrasound and 99m Tc-DMSA will not distinguish between idiopathic cases and those with a known genetic cause. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; HNF1B, hepatocyte nuclear factor 1β; NPHP, nephronophthisis; PKD1, polycystic kidney disease 1; PKD2, PKD2, polycystic kidney disease 2; PKHD1, polycystic kidney and hepatic disease 1; 99m Tc-DMSA renography, technetium-99m-labelled dimercaptosuccinic acid; TSC1, tuberous sclerosis 1; TSC2, tuberous sclerosis 2; US, ultrasound; VHL, Von Hippel-Lindau tumour suppressor, E3 ubiquitin protein ligase.
publications describing HNF1B-associated disease. 7 Liver dysfunction is a common clinical finding 9,22 that usually manifests as an asymptomatic rise in the levels of liver enzymes, particularly alanine aminotransferase and γ-glutamyl transferase. 25 Four patients have been reported with neonatal cholestasis, with the results of liver biopsy indicating a reduction in the number of intrahepatic bile ducts. 19, 23, 83, 84 This infrequent phenotype is consistent with the paucity of bile ducts seen in mice with a liver-targeted deletion of Hnf1b. 85 Electron microscopy has demonstrated a reduction of normal primary cilia on the epithelial cells of the bile duct among patients with HNF1B mutations, which could also contribute to cholestasis. 86 Other clinical features Increasing interest has focused on whether HNF1B gene anomalies might be associated with neurodevelopmental disorders. A 1.4 Mb deletion at chromosome 17q12, which includes the HNF1B gene, was found in 18 of 15,749 patients referred for clinical genetic testing for autism spectrum disorders, developmental delay or cognitive impairment. 87 Seizures, structural brain abnormalities, mild facial dysmorphic features and macrocephaly have also been reported. 88, 89 The deleted stretch of DNA contains 15 genes; therefore, it is not clear what genetic mechanism gives rise to these observed neurodevelopmental phenotypes. In a cohort of 53 children with whole gene deletion of HNF1B and cystic kidney disease, three had a diagnosis of autism. 89 This finding was more common than the 1:150-1:300 prevalence of autism recorded in the general paediatric population and suggests further work is needed to ascertain the exact incidence of autism in this group of patients. Nephrologists should therefore be aware of this potential association to ensure that referral to appropriate psychiatric services can be made where applicable.
Early development of hyperparathyroidism may be a previously unrecognized feature of HNF1B-associated disease. Relatively high levels of parathyroid hormone (PTH) ranging from 6.6 pmol/l to 16.4 pmol/l, given the degree of decline in renal function, have been reported in six of 11 unselected patients with known HNF1B gene anomalies undergoing follow-up at a single centre. Five of these six patients had hypomagnesaemia, which usually inhibits the release of PTH, whereas their plasma levels of calcium and phosphate were within the normal range. In vitro studies demonstrated that wildtype HNF1B can inhibit transcription of PTH, whereas mutant HNF1B lost this function. 90 Other clinical features, including hearing loss and pyloric stenosis, have been reported in a small number of individuals with an HNF1B mutation. 25 Nevertheless, a causal link with HNF1B gene anomalies remains to be established.
Areas for future research HNF1B-associated disease was first described in 1997, and despite the subsequent identification of many affected patients, research questions still remain regarding its functional and pathological consequences. The prevalence of HNF1B gene anomalies in the general population is unknown and it is likely that many cases remain undetected owing to the variable phenotype and frequency of de novo gene deletions. One study identified three individuals with an HNF1B deletion from a group of 258 patients who met the clinical criteria for MODY and were not known to have renal disease. 51 Gene mutations were not assessed in this study so it is possible that other patients in this cohort had HNF1B-associated disease that was not identified. This observation highlights the requirement for an improved method of patient selection for genetic testing so that HNF1B-associated disease can be recognized and treated appropriately. One study has described an HNF1B score to be used as part of an algorithm for diagnosing HNF1B-associated disease. 91 This score was created using a weighted combination of clinical features based on the frequency and specificity in HNF1B-associated disease reported in the published literature. The most discriminative characteristics included renal hyperechogenicity, cystic kidneys, MODY, pancreatic hypoplasia or exocrine insufficiency and genital tract abnormalities. A total of 15 different clinical features are assessed in the score, which reflects the wide hetero geneity of organ involvement seen in this disease. It should, therefore, prove to be a useful tool for selecting patients for HNF1B testing but first requires validation in prospective studies in different populations. 91 Studies showing a link between large deletions at chromo some 17q12 and neurodevelopmental disorders, has led to speculation about the underlying mechanism and whether deletion of HNF1B within this region may be involved. 87, 88 HNF1B gene anomalies have not previously been associated with abnormalities of neural development and function. Further investigation in a large cohort of individuals with both HNF1B mutations and deletions is therefore required, and would have important implications for patient management.
The reasons for phenotypic variation in HNF1B-associated disease remain poorly understood. It is uncertain if such variation reflects the functional effects of different gene anomalies; stochastic variation resulting from minor differences in temporal expression in early development; genetic modifiers; or the contribution of additional neighbouring deleted genes in those patients with the 1.5 Mb deletion that includes HNF1B. Comparing large groups of patients, for example those with extreme phenotypic variation and those with wholegene deletions versus coding or splice site mutations, could help to identify some of the determinants of this varied phenotype. It will also be important to establish a prospective paediatric cohort, as the follow-up of affected children and adolescents will allow for the development and progression of different clinical features to be studied.
Discoveries in zebrafish and mouse models have helped to identify how Hnf1b functions during different stages of renal development; however, much remains to be learned about the complex molecular pathways that are involved. The increasing use of next generation sequencing, which enables sequencing of the entire human genome within several days, is predicted to identify novel genes involved in CAKUT over the next few years. 92 These gene products may act upstream or downstream of HNF1B and will therefore help to elucidate further the role of HNF1B in nephrogenesis.
Conclusions
HNF1B first generated interest in 1997 as a potential candidate gene for MODY; it is now known to be the most frequent monogenic cause of developmental renal disease. Mutations in HNF1B result in a multisystem disorder and some work has suggested that neuro developmental features, such as autism spectrum dis orders, might be part of the phenotype among individuals with a 17q12 deletion that involves the HNF1B gene. HNF1B-associated disease is charac terized by marked clinical heterogeneity and a positive family history is often lacking; as a result, many patients are likely to have been missed. Further work is required to improve the identification of appropriate patients for genetic testing and to understand the phenotypic variation. HNF1B genetic testing should be considered for all patients with developmental renal disease, particularly if renal cysts or hyperechogenicity are detected or other extra-renal clinical features are present.
Review criteria
PubMed was searched using the following terms: "maturity onset diabetes mellitus of the young type 5", "renal cysts and diabetes mellitus syndrome", "hepatocyte nuclear factor 1 beta", "transcription factor 2", "HNF1beta", "HNF1B", "TCF2", "MODY5" and "RCAD". The search was restricted to articles published in English between January 1997 and June 2014. Other references and relevant articles published before 1997 were derived from the authors' knowledge of the published literature.
